Friday, November 13th, 2026

Dear Becker & Duchenne Community members,

Servier recently announced that the GRAND CANYON study did not meet its primary nor key secondary endpoints. Following these results, we have made the difficult decision to stop the research studies for sevasemten for both Becker and Duchenne muscular dystrophy.

We know that this news is deeply disappointing for both communities and recognize the hope that people have placed in sevasemten as a potential treatment option for Becker and Duchenne.

The GRAND CANYON study results show that sevasemten did not provide any benefit on primary or key secondary functional endpoints. A Governance Committee also reviewed the data and came to the same conclusion. We want to reassure you that the study demonstrated a similar safety and tolerability profile to prior studies. No new Adverse Events nor safety concerns have been observed, and the overall safety profile remains largely unchanged from prior studies.

Results from the LYNX and FOX phase 2 dose finding studies in Duchenne have also been reviewed by a Governance Committee, which determined that there is not enough evidence to continue development in Duchenne.

While these results were not what we had hoped for, there is still much to learn from these studies. Our teams will continue to conduct an in-depth analysis of the data to better understand the results. We are committed to sharing what we learn with the Becker and Duchenne communities, as well as the broader scientific community, so that this knowledge can help inform and advance future research.

We want to acknowledge the extraordinary contributions of the individuals and families who participated in our clinical studies. We recognize the time, effort, and trust that participation in clinical research requires, and we are deeply grateful to every participant, caregiver, investigator, and clinical team who made this work possible. **Your contributions are meaningful, and the knowledge gained through this research will remain an important part of our collective understanding of Becker and Duchenne.**

Over the years, we have had the privilege of building meaningful relationships across the community. **We will honor the commitments we have already made to our community partners** and thoughtfully evaluate opportunities for future engagement and support.

We have also witnessed the tremendous momentum that has grown within the Becker community in recent years. Our sincere hope is that the connections, collaboration, and progress made together will continue well beyond this clinical program. Additionally, we

are determining how best to continue to support the Becker community, balancing Servier and community sustainability needs.

We understand that this news brings uncertainty and may raise questions about what comes next. While we do not have all the answers today, we will continue to engage with the community as we learn more. We plan to hold webinars soon. Thank you for the trust you have placed in us, for the perspectives you have shared, and for allowing us to be part of this community.

If you have any questions, please reach out to your clinician, your local Patient Advocacy Organization or us at scientificinformation@servier.com.

With sincere gratitude,

Servier Patient Advocacy Team

Abby, Katherine, & Sarah